By Hugo Francisco de Souza Reviewed by Susha Cheriyedath, M.Sc. Mar 3 2026 A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, delivering powerful weight loss while simultaneously protecting the heart, kidneys, and metabolic health. Review: GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits . Image Credit: Gecko Studio / Shutterstock In a recent review published in